Controlled non-randomised before-after study evaluating the impact of a focused recommendation card on vaccination rates of oncological patients-The Easy Vaccination in Oncology (EVO) strategy.
cancer
infectious diseases
prevention
vaccination
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
14
09
2022
received:
18
02
2022
accepted:
22
09
2022
pubmed:
13
10
2022
medline:
30
11
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
By implementing a focused must-have vaccination strategy (Easy Vaccination in Oncology [EVO]), we aimed to increase rates for high-impact vaccinations (Streptococcus pneumoniae, influenza, herpes zoster and hepatitis B) in the at-risk population of oncological patients. In this German multicentre interventional non-randomised controlled two-arm open trial with repeated cross-sectional data collection, we evaluated the EVO strategy as an easy to implement approach. Vaccination rates were assessed in the outpatient setting and re-assessed after 3 months. A generalised linear mixed model (GLMM) was used to assess the primary endpoint (Streptococcus pneumoniae vaccination rates according to recommendations), taking clustering within clinics into account. Vaccination rates substantially increased in the intervention group; Streptococcus pneumoniae +21.5% (+16.7% according to recommendations), influenza +12.2%, herpes zoster +13.3% (+13.6% age group 50+), and hepatitis B +11%. Vaccination rates in the control group tended to decrease or increase only moderately (-5.8% [-3.8%], +7.4%, +2.1% [1.4%], and -1.7%, respectively). GLMM showed significant effect of the intervention (OR 7.50, 95% CI 2.18-25.80, p = 0.001). This easy-to-implement and resource-saving approach has the potential to increase vaccination rates in oncological patients and to have a considerable impact protecting oncological patients from preventable infectious diseases. The study was registered at the German Resister for Clinical Studies (DRKS) under DRKS00020118.
Types de publication
Clinical Trial
Controlled Clinical Trial
Journal Article
Langues
eng
Pagination
e13725Subventions
Organisme : Pfizer Pharma GmbH
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Ariza-Heredia, E. J., & Chemaly, R. F. (2015). Practical review of immunizations in adult patients with cancer. Human Vaccines & Immunotherapeutics, 11(11), 2606-2614. https://doi.org/10.1080/21645515.2015.1062189
Berglund, A., Willén, L., Grödeberg, L., Skattum, L., Hagberg, H., & Pauksens, K. (2014). The response to vaccination against influenza a(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncologica (Stockholm, Sweden), 53(9), 1212-1220. https://doi.org/10.3109/0284186X.2014.914243
Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., Sohn, S. K., Rodriguez Macías, G., Chiou, T. J., Quiel, D., Aoun, M., Navarro Matilla, M. B., de la Serna, J., Milliken, S., Murphy, J., McNeil, S. A., Salaun, B., Di Paolo, E., Campora, L., … Zoster-039 study group. (2019). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet. Infectious Diseases, 19(9), 988-1000. https://doi.org/10.1016/S1473-3099(19)30163-X
Gudiol, C., Royo-Cebrecos, C., Laporte, J., Ardanuy, C., Garcia-Vidal, C., Antonio, M., Arnan, M., & Carratalà, J. (2016). Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirology (Carlton, Vic.), 21(8), 1411-1418. https://doi.org/10.1111/resp.12848
Hong, K., Zhou, F., Tsai, Y., Jatlaoui, T. C., Acosta, A. M., Dooling, K. L., Kobayashi, M., & Lindley, M. C. (2021). Decline in receipt of vaccines by Medicare beneficiaries during the COVID-19 pandemic-United States, 2020. MMWR. Morbidity and Mortality Weekly Report, 70(7), 245-249. https://doi.org/10.15585/mmwr.mm7007a4
Laws, H.-J., Baumann, U., Bogdan, C., Burchard, G., Christopeit, M., Hecht, J., Heininger, U., Hilgendorf, I., Kern, W., Kling, K., Kobbe, G., Külper, W., Lehrnbecher, T., Meisel, R., Simon, A., Ullmann, A., de Wit, M., & Zepp, F. (2020). Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 63(5), 588-644. https://doi.org/10.1007/s00103-020-03123-w
Monier, A., Puyade, M., Hernanz, M. P. G., Bouchaert, P., Leleu, X., Tourani, J. M., Roblot, F., & Rammaert, B. (2020). Observational study of vaccination in cancer patients: How can vaccine coverage be improved? Medecine et Maladies Infectieuses, 50(3), 263-268. https://doi.org/10.1016/j.medmal.2019.11.006
Niehues, T., Bogdan, C., Hecht, J., Mertens, T., Wiese-Posselt, M., & Zepp, F. (2017). Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen(I) Grundlagenpapier. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 60(6), 674-684. https://doi.org/10.1007/s00103-017-2555-4
Poethko-Müller, C., & Schmitz, R. (2013). Impfstatus von Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 56(5-6), 845-857. https://doi.org/10.1007/s00103-013-1693-6
Rabello, L. S. C. F., Silva, J. R. L., Azevedo, L. C. P., Souza, I., Torres, V. B. L., Rosolem, M. M., Lisboa, T., Soares, M., & Salluh, J. I. F. (2015). Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: A prospective cohort study. PLoS ONE, 10(3), e0120544. https://doi.org/10.1371/journal.pone.0120544
Rieck, T., Steffen, A., Schmid-Küpke, N., Feig, M., Wichmann, O., & Siedler, A. (2020). Impfquoten bei Erwachsenen in Deutschland - Aktuelles aus der KV-Impfsurveillance und der Onlinebefragung von Krankenhauspersonal OKaPII. https://doi.org/10.25646/7658
Rieger, C. T., Liss, B., Mellinghoff, S., Buchheidt, D., Cornely, O. A., Egerer, G., Heinz, W. J., Hentrich, M., Maschmeyer, G., Mayer, K., Sandherr, M., Silling, G., Ullmann, A., Vehreschild, M. J. G. T., von Lilienfeld-Toal, M., Wolf, H. H., Lehners, N., & German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO). (2018). Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29(6), 1354-1365. https://doi.org/10.1093/annonc/mdy117
Ständige Impfkommission (STIKO) Beim Robert Koch-Institut. (2020). Stellungnahme der Ständigen Impfkommission Durchführung von empfohlenen Schutzimpfungen während der COVID-19-Pandemie. https://doi.org/10.25646/6858